Nigeria’s 2023 Health Facility Registry counts 38,645 health facilities nationwide. On paper, that looks like a healthcare system approaching maturity.
It isn’t.
The WHO’s 2025 Nigeria Health Systems and Services Profile makes it clear: primary healthcare remains the weakest tier of service delivery, undermined by gaps in infrastructure, specialist services, emergency care, and referral systems.
Here’s the reframe every serious investor needs: Nigeria doesn’t have a shortage of buildings called hospitals. It has a shortage of functional healthcare infrastructure — reliable power, water, laboratories, diagnostic equipment, cold chain, digital connectivity, trained personnel, and supply chains that actually work together.
That gap between facility and functional is not just a development statistic. It’s the clearest infrastructure investment thesis on the African continent right now.
A Government Actively Building the On-Ramp for Private Capital
Nigeria’s National Primary Health Care Development Agency has set a public target: 17,600 fully functional primary healthcare facilities by 2027, with at least one in every political ward. As of August 2025, only 1,295 had been revitalised — with 3,469 more in progress.
Do the arithmetic. Government capacity alone will not hit that target. Which means private capital, equipment financing, energy partnerships, and operating expertise aren’t optional extras to Nigeria’s healthcare strategy — they are the only realistic path to closing the gap.
Add to that:
- Nigeria Health Sector Renewal Investment Initiative, targeting functional PHC expansion
- Nigerian Sovereign Investment Authority healthcare programme, built around diagnostic centres and cardiac catheterisation capacity
- World Bank’s Nigeria Health Compact, explicitly inviting private-sector participation in facility upgrades, emergency medical services, and infrastructure financing
Nigeria has moved from acknowledging this deficit to actively financing its closure. For investors, that’s the single most important signal in this market today — and most people haven’t clocked it yet.
Where the Capital Is Actually Going
In The Gap Is the Opportunity, I break down five specific frontiers where the constraint is clearest and the commercial model most defensible:
- Diagnostic infrastructure — imaging, laboratories, and the leasing/managed-service models replacing one-off equipment sales
- Medical equipment financing — Nigeria imports over 98% of its medical equipment; the opportunity isn’t the product gap, it’s who finances and maintains it
- Power and energy for healthcare — solar and distributed energy are now a healthcare investment category, not an adjacent one
- Pharmaceutical cold chain and logistics — the infrastructure carrying the medicine is as commercially important as the medicine itself
- Private healthcare infrastructure — but treated market-by-market, not as a single “Nigeria” bet (Lagos is not Kano)
I also cover how this same playbook is already replicating in Kenya and Ghana, and lay out a five-point due-diligence framework for anyone about to commit capital.
Introducing: The Gap Is the Opportunity
This is the thinking behind my new book: The Gap Is the Opportunity: Nigeria’s Healthcare Infrastructure Gap and the Next Decade of Investment.
It’s written specifically for:
- ✅ International healthcare executives evaluating Nigeria as a market
- ✅ Investors and family offices looking for defensible, government-backed infrastructure plays in Africa
- ✅ Nigerian and regional entrepreneurs seeking the right global partnerships
- ✅ Industry professionals who want a sharper, data-grounded view of where healthcare capital is heading next
No fluff. No “Africa is rising” clichés. Just the data, the government signals, the specific investment frontiers, and a due-diligence framework built from years of on-the-ground market entry work.
I’m Making This Available to My Network Now
If you’re an investor, executive, or entrepreneur seriously exploring the Nigerian (or wider African) healthcare and pharmaceutical sector, I’d like to get this into your hands.
Comment “GAP” below or send me a DM, and I’ll personally share how to get a copy — and I’m happy to jump on a short call with anyone weighing a real market-entry decision this quarter.
If you know someone in your network who’s been asking “is there a market in Nigeria’s healthcare sector” — tag them below. This is written for exactly that conversation.
Jean Claude Agbortem Obi is a business consultant specialising in market entry, business development and commercial expansion across African markets, with a particular focus on FMCG and pharmaceutical businesses.
Through Routrix Africa, he works with international and African companies seeking to navigate the complexities of African markets, including distributor selection, route-to-market development, market intelligence and commercial expansion.
His perspective is grounded in a practical understanding of the realities that determine whether a brand succeeds beyond the boardroom and reaches the consumer at the point of purchase.
His central philosophy is simple: African market entry should not end with getting into the market. The real objective is building a sustainable pathway to commercial success.